Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP Signaling.

• Tác giả: Andrew Beardsley, Sophia Durney, Andrei Goga, Hani Goodarzi, Mary-Kate Hayward, Nathaniel P Meyer, Rachel Nakagawa, Vishvak Subramanyam, Daniel Van de Mark, Valerie M Weaver, Harrison Wismer
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : bioRxiv : the preprint server for biology , 2025
• Bộ sưu tập: NCBI
• ID: 215470

Tóm tắt

Non-small cell lung cancers (NSCLC) harboring common mutations in EGFR and KRAS characteristically respond transiently to targeted therapies against those mutations, but invariably, tumors recur and progress. Resistance often emerges through mutations in the therapeutic target or activation of alternative signaling pathways. Mechanisms of acute tumor cell resistance to initial EGFR (EGFRi) or KRAS